(firstQuint)A Study of MABp1 in Patients With Hidradenitis Suppurativa.

 Phase 2, open label, dose escalation study of two dose cohorts of MABp1 in patients with moderate to severe Hidradenitis Suppurativa.

 The study is multicenter and will consist of two dose levels: MABp1 administered subcutaneously at a dose of 200 mg weekly (12 doses) and MABp1 administered subcutaneously at a dose of 400 mg weekly (12 doses).

 Patients will be followed for 12 weeks to allow for assessment of safety and preliminary efficacy.

.

 A Study of MABp1 in Patients With Hidradenitis Suppurativa@highlight

Phase 2 study of MABp1 in patients with moderate to severe Hidradenitis Suppurativa.

